Clostridium News and Research

RSS

BioSpecifics Technologies revenues increases by 100% for the third quarter ended September 30, 2009

BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009.

6 Nov 2009

Unexpected consequences emerge in patients who are prescribed PPI medications for reflux diseases

Despite being highly effective and beneficial for many patients, unexpected consequences are emerging in patients who are prescribed proton pump inhibitors (PPIs) for reflux diseases. Physicians are warned to monitor these effects and prescribe these medications carefully, according to a new commentary published in the November 2009 issue of Otolaryngology - Head and Neck Surgery.

2 Nov 2009

NIH awards Excelimmune grant to develop treatment for Clostridium difficile infection

Excelimmune, Inc. (www.excelimmune.com) announced today that the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant to support research aimed at developing new treatments for Clostridium difficile (C. difficile) infection, employing Excelimmune’s expertise in developing novel antibody therapies for human disease.

28 Oct 2009

Auxilium Pharmaceuticals reports increased net revenues of $42.1 million in third quarter 2009

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced financial results and operational highlights for the quarter ended September 30, 2009. For the third quarter of 2009, Auxilium reported net revenues of $42.1 million compared to net revenues of $32.6 million in the third quarter of 2008.

28 Oct 2009

HHS funds projects to combat health care-associated infections

HHS Secretary Kathleen Sebelius today announced the award of $17 million to fund projects to fight costly and dangerous health care-associated infections, or HAIs.

28 Oct 2009

Stomach infection on the rise in outpatient settings; symptoms can range from diarrhea to life-threatening inflammation

Mayo Clinic researchers have found that a sometimes deadly stomach bug, Clostridium difficile, (http://www.mayoclinic.org/c-difficile/) is on the rise in outpatient settings.

27 Oct 2009

BD to acquire HandyLab

BD (Becton, Dickinson and Company)announced today that it signed a definitive agreement to acquire HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms. The acquisition is subject to regulatory approvals and is expected to close during the first quarter of fiscal year 2010. The financial terms of the agreement were not disclosed.

From BD (Becton, Dickinson and Company) 24 Oct 2009

HHS funds $17M for fight against costly and dangerous health care-associated infections

HHS Secretary Kathleen Sebelius today announced the award of $17 million to fund projects to fight costly and dangerous health care-associated infections, or HAIs.

24 Oct 2009

Eat healthy food to keep bacteria in the gut healthy

Healthy eating, not supplements, is the best way to keep the good bacteria in your gut healthy, says a dietitian and researcher.

22 Oct 2009

Optimer Pharmaceuticals to present additional data on fidaxomicin at the 47th IDSA meeting

Optimer Pharmaceuticals, Inc. announced that additional data related to fidaxomicin, the Company's lead developmental product candidate for the treatment of Clostridium difficile infection, will be presented at the 47th Annual Meeting of the Infectious Disease Society of America (IDSA) to be held at The Philadelphia Convention Center in Philadelphia, Pennsylvania October 29 through November 1, 2009.

20 Oct 2009

Handwashing with soap is the best way to control flu and respiratory infections

People are more likely to wash their hands when they have been shamed into it, according to a study by the London School of Hygiene & Tropical Medicine

15 Oct 2009

Pennsylvania Patient Safety Authority's initiative to raise awareness of healthcare-associated infections

The Pennsylvania Patient Safety Authority supports "International Infection Prevention Week," October 18-24, 2009, to raise awareness of the need to protect patients and the public from healthcare-associated infections (HAIs).

14 Oct 2009

Automated SafetySurveillor system to detect healthcare-associated infections

The Premier healthcare alliance today announced that Bon Secours St. Francis Medical Center of Midlothian, Va., selected Premier’s SafetySurveillor® Web-based infection tracking and antimicrobial utilization tool. More than 270 hospitals use SafetySurveillor to help prevent healthcare-associated infections (HAIs) and optimize antibiotic use, thereby protecting patients more effectively while safely reducing hospital costs.

30 Sep 2009

Clostridium difficile's five genetic regions identified

Five genetic regions have been identified that are unique to the most virulent strain of Clostridium difficile (C. difficile), the hospital superbug. Researchers writing in BioMed Central's open access journal Genome Biology studied the genome of the bacterium, looking for genes relating to motility, antibiotic resistance and toxicity.

25 Sep 2009

FDA Advisory Committee recommends marketing approval for Auxilium's XIAFLEX to treat Dupuytren's contracture

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) recommended by a unanimous vote of 12 to 0 that XIAFLEX™ (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, be granted marketing approval by the FDA for the treatment of Dupuytren's contracture.

17 Sep 2009

BioSpecifics Technologies' XIAFLEX receives marketing approval from FDA

BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products, today announced that the Arthritis Advisory Committee appointed by the U.S.

17 Sep 2009

Phase III clinical trial results of XIAFLEX published in a journal

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products today announced results of the pivotal CORD I Phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic for the nonsurgical treatment of Dupuytren's disease, was published in today's edition of the New England Journal of Medicine.

4 Sep 2009

Recurrence of Clostridium difficile infection is a growing area of concern in hospitals

Arlington Medical Resources (AMR) and Decision Resources find that relapse or recurrence of infections is the most challenging aspect of treating Clostridium difficile infections in the hospital setting.

3 Sep 2009

CORD I phase III clinical trial results of XIAFLEX published

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that The New England Journal of Medicine (NEJM) has published in its September 3rd edition, the Company's pivotal CORD I Phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum) a novel, first-in-class, biologic for the nonsurgical treatment of Dupuytren's contracture.

3 Sep 2009

New method for treating hand disorder discovered

Researchers in the Department of Orthopaedics at Stony Brook University Medical Center have developed an injectable form of the enzyme, collagenase, that significantly improves outcomes of Dupuytren's contracture (or disease), a debilitating disorder caused by progressive accumulation of collagen that deforms fingers and limits motion. Reported in September 3, 2009, issue of The New England Journal of Medicine, the study involved treatment of 308 patients with Duputren's disease in 16 sites nationwide. The results indicate that the injections are safe and effective.

3 Sep 2009

Clostridium News and Research

BioSpecifics Technologies revenues increases by 100% for the third quarter ended September 30, 2009

Unexpected consequences emerge in patients who are prescribed PPI medications for reflux diseases

NIH awards Excelimmune grant to develop treatment for Clostridium difficile infection

Auxilium Pharmaceuticals reports increased net revenues of $42.1 million in third quarter 2009

HHS funds projects to combat health care-associated infections

Stomach infection on the rise in outpatient settings; symptoms can range from diarrhea to life-threatening inflammation

BD to acquire HandyLab

HHS funds $17M for fight against costly and dangerous health care-associated infections

Eat healthy food to keep bacteria in the gut healthy

Optimer Pharmaceuticals to present additional data on fidaxomicin at the 47th IDSA meeting

Handwashing with soap is the best way to control flu and respiratory infections

Pennsylvania Patient Safety Authority's initiative to raise awareness of healthcare-associated infections

Automated SafetySurveillor system to detect healthcare-associated infections

Clostridium difficile's five genetic regions identified

FDA Advisory Committee recommends marketing approval for Auxilium's XIAFLEX to treat Dupuytren's contracture

BioSpecifics Technologies' XIAFLEX receives marketing approval from FDA

Phase III clinical trial results of XIAFLEX published in a journal

Recurrence of Clostridium difficile infection is a growing area of concern in hospitals

CORD I phase III clinical trial results of XIAFLEX published

New method for treating hand disorder discovered

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News